Flavobacterium meningosepticum ventriculitis: in vivo and in vitro results with the combinations rifampicin-erythromycin and mezlocillin-cefoxitin.
A case of Flavobacterium meningosepticum ventriculitis is described in which the failure of therapy with a combination of rifampicin and erythromycin is attributed to inadequate antibiotic levels in cerebrospinal fluid. The successful eradication of the organism was achieved with the use of mezlocillin and cefoxitin given by the intravenous and intraventricular route. In vitro sensitivity tests of recently isolated strains of Flavobacterium meningosepticum suggested that the combination mezlocillin and cefoxitin is more often synergistic than rifampicin and erythromycin.
D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000134:cerebrospinal fluid; D001424:Bacterial Infections / Q000188:drug therapy; D002440:Cefoxitin / Q000008:administration & dosage*; D002552:Cerebral Ventricles; D004359:Drug Therapy, Combination; D004660:Encephalitis / Q000188:drug therapy*; D004917:Erythromycin / Q000008:administration & dosage*; D005260:Female; D005417:Flavobacterium / Q000187:drug effects*; D006801:Humans; D007223:Infant; D008802:Mezlocillin; D008826:Microbial Sensitivity Tests; D010406:Penicillins / Q000008:administration & dosage*; D012293:Rifampin / Q000008:administration & dosage*
D000900:Anti-Bacterial Agents; D010406:Penicillins; D004917:Erythromycin; D002440:Cefoxitin; D008802:Mezlocillin; D012293:Rifampin